• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24463 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2027     Norwegian Medical Products Agency (NOMA) [Wearable cardioverter defibrillator (LifeVest) for people with high risk of sudden cardiac arrest: a single technology assessment]
2027     Belgian Health Care Knowledge Centre (KCE) Review of new oncology indications for the use of positron emission tomography (PET-scans) (Study 2024-12)
2026     Health Information and Quality Authority (HIQA) Protocol for a systematic review on the association between alcohol consumption and mental health outcomes
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal shockwave therapy for treating chronic skin wounds: pressure ulcers, diabetic foot ulcers, and vascular wounds (venous and/or arterial)]
2026     Scottish Health Technologies Group (SHTG) Virtual wards
2026     Health Information and Quality Authority (HIQA) Scalable Training and Knowledge Exchange on guideline development for patients, public, and healthcare professionals (The STAKEholder Project)
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [rTMS: Evidence report for the S3 guideline on chronic tinnitus]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [VNS: Evidence report for the S3 guideline on chronic tinnitus]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimodal ES: Evidence report for the S3 guideline on chronic tinnitus]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [TMNMT: Evidence report for the S3 guideline on chronic tinnitus]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [CR neuromodulation: Evidence report for the S3 guideline on chronic tinnitus]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Local hyperbaric oxygen therapy for diabetic foot ulcers]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Psychological interventions for ARFID: Evidence report for the S3 guideline on the diagnosis and treatment of eating disorders]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug interventions for ARFID: Evidence report for the S3 guideline on the diagnosis and treatment of eating disorders]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Psychological interventions following obesity surgery: Evidence report for the S3 guideline on the diagnosis and treatment of eating disorders]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug interventions following obesity surgery: Evidence report for the S3 guideline on the diagnosis and treatment of eating disorders]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between quantity of services and quality of treatment outcome in corrective surgery of Hirschsprung's disease]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of endovascular treatment using transarterial radioembolization for intermediate and advanced hepatocellular carcinoma]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Exercise programs for cancer patients over 65 years of age undergoing chemotherapy. Systematic review]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety, clinical effectiveness, and cost-effectiveness of neonatal screening for beta-ketothiolase deficiency and classic galactosemia. Update]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Economic evaluation of a booster dose of Tdap vaccine in adolescents]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fundus photography for the diagnosis of diabetic retinopathy]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Local hyperbaric oxygen therapy for diabetic foot ulcers]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP "Chronic obstructive pulmonary disease (COPD)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of pelvic floor training during pregnancy for the prevention of pre and postnatal urinary incontinence]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy and safety of model-informed precision dosing of biologic agents]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Neurosurgical robot for electrode implantation, brain biopsies and spinal surgery]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Artificial intelligence software to detect viable tissue in stroke patients on CT or perfusion MRI of the skull]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Telemedicine for the follow-up of post-stroke patients]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, clinical and cost-effectiveness of neonatal screening for type 1 citrullinaemia, trifunctional protein deficiency, holocarboxyl synthetase deficiency, argininosuccinic aciduria and 3-methylcrotonyl-CoA carboxylase deficiency]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Safety, clinical effectiveness and cost-effectiveness of neonatal screening for Pompe disease]
2026     Belgian Health Care Knowledge Centre (KCE) Assessment of a mobile application in the rehabilitation of patients undergoing primary knee or hip arthroplasty (Study 2020-01)
2026     Belgian Health Care Knowledge Centre (KCE) Economic evaluation based on ‘PRECISe’, a randomised clinical trial funded by the KCE Trials programme (Study 2024-92)
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Barriers and facilitators when implementing guidelines in health and social care for the elderly]
2026     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Nirmatrelvir plus ritonavir (Paxlovid)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the lower age limit and frequency of early-detection colonoscopy in the colorectal cancer screening programme]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acupuncture for migraine prophylaxis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Newborn screening for metachromatic leukodystrophy]
2026     Swiss Federal Office of Public Health (FOPH) Valerian extracts for sleep disorders, anxiety or restlessness
2026     Swiss Federal Office of Public Health (FOPH) Ginkgo biloba in patients with decreasing mental performance, peripheral arterial occlusive disease, vertigo or tinnitus
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [X-ray image of the lung: Can artificial intelligence support the analysis of X-ray images?]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Quality of sleep: Can taking melatonin as a dietary supplement, e.g. in the form of tablets, sprays or soft gums, help to improve sleep?]
2026     Swiss Federal Office of Public Health (FOPH) Thermoablation for benign thyroid nodules
2026     Swiss Federal Office of Public Health (FOPH) Injection therapies with corticosteroids for chronic tendinopathy or enthesopathy
2026     Swiss Federal Office of Public Health (FOPH) Superficial/deep heat in physiotherapy for musculoskeletal conditions
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Reinforced foster homes]
2025     NIHR Health Technology Assessment programme An exploration of the factors influencing successful implementation, delivery and outcomes in an intensive care sedation study: process evaluation of the A2B RCT
2025     NIHR Health Technology Assessment programme High or low dose oxytocin for nulliparous women delayed in the first stage of labour: the HOLDS RCT
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of a standardised diagnostic assessment for children and adolescents with emotional difficulties: the STADIA multi-centre RCT
2025     NIHR Health Technology Assessment programme The Knee Arthroplasty versus Joint Distraction Study for Osteoarthritis (KARDS): lessons learnt from an internal pilot trial
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Presumed penicillin allergies: risk assessment for optimal and safe use of betalactams]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [External beam radiotherapy delivered by ultra-hypofractionation for the treatment of prostate cancer]
2025     Haute Autorite de sante (HAS) [Next generation sequencing gene panel using circulating tumor DNA for medical lung cancer care]
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of technologies for the assessment of attention deficit hyperactivity disorder: a systematic review and economic model
2025     NIHR Health Services and Delivery Research programme Evidence of the impact on and views of NHS staff following a colleague’s suicide to inform postvention guidance: a multi-methods study
2025     NIHR Health Technology Assessment programme Effectiveness of Escitalopram and Nortriptyline on Depressive Symptoms in Parkinson’s disease: the ADepT-PD RCT pilot
2025     NIHR Health Technology Assessment programme Swabs versus tissue samples for infected diabetic foot ulcers: the CODIFI2 RCT
2025     NIHR Health Technology Assessment programme RecUrrent Intra-articular Corticosteroid injections in Osteoarthritis: the RUbICOn mixed-methods study
2025     NIHR Health Technology Assessment programme Minimally invasive thoracoscopically-guided right minithoracotomy versus conventional sternotomy for mitral valve repair: the UK Mini Mitral multicentre RCT
2025     NIHR Health Technology Assessment programme Control, Fludrocortisone or Midodrine for the treatment of Orthostatic Hypotension: CONFORM-OH pilot RCT and economic evaluation
2025     NIHR Health Technology Assessment programme Treatment effect modifiers of cognitive behaviour therapy in people with psychosis: an individual participant data meta-analysis of RCTs
2025     NIHR Health Technology Assessment programme Procalcitonin evaluation of antibiotic use in COVID-19 hospitalised patients: The PEACH mixed methods study
2025     NIHR Health Services and Delivery Research programme Development and implementation of a digital health intervention in routine care for long COVID patients: a comprehensive synopsis
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Omjjara (myelofibrosis - MF)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Vitrakvi (NTRK gene fusions in solid tumors)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Peyona (Apnea of prematurity - AOP)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Onivyde (Advanced pancreatic cancer- first line treatment)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Kepida (breast cancer)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Fespixon cream (Diabetic foot ulcers- DFUs)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Enstilar (Psoriasis vulgaris)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Enspryng (neuromyelitis optica spectrum disorder- NMOSD)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Blincyto ( B-lineage acute lymphoblastic leukemia)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Xeljanz (Juvenile Idiopathic Arthritis - JIA)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Vanflyta (Acute Myeloid Leukemia - AML)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Vafseo (dialysis-dependent chronic kidney disease - DD-CKD)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Upstaza (AADC deficiency)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Trodelvy (Breast Cancer)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Tecentriq (Hepatocellular Carcinoma - HCC)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Piasky (Paroxysmal Nocturnal Hemoglobinuria - PNH)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Minjuvi (DLBCL)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Fustron (Breast Cancer)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Calquence (Chronic Lymphocytic Leukemia - CLL)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Brukinsa (Chronic Lymphocytic Leukemia - CLL)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Bavencio (Urothelial Carcinoma - UC)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Xinclame (ophthalmic antibiotic)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Scemblix (chronic myeloid leukaemia - CML)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Qinlock (GIST)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Epkinly (DLBCL)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Columvi (DLBCL)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Cen-Capto (Pediatric heart failure)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report- Tecentriq (NSCLC-first line treatment)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report- Lynparza(prostate cancer- PC)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Lynparza (Breast cancer- BC)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Lynparza (advanced ovarian cancer- AOC)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Keytruda (Triple Negative Breast Cancer-TNBC)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Keytruda (metastatic non-squamous non-small cell-NSCLC) lung cancer)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Keytruda (colorectal cancer - CRC)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report- Beovu (Neovascular (wet) age-related macular degeneration, AMD & polypoidal choroidal vasculopathy, PCV & Diabetic Macular Edema, DME)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Voxzogo (Achondroplasia - ACH)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report-Tecvayli (Relapsed or refractory multiple myeloma - RRMM)]